Machairas Nikolaos, Prodromidou Anastasia, Molmenti Ernesto, Kostakis Ioannis D, Sotiropoulos Georgios C
Second Department of Propaedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Department of Surgery, North Shore University Hospital, Manhasset, New York, USA.
J Gastrointest Oncol. 2017 Dec;8(6):1100-1108. doi: 10.21037/jgo.2017.08.08.
The recommended management of liver metastases (LM) from gastrointestinal stromal tumors (GISTs) disease consists of perioperative administration of tyrosine kinase inhibitors (TKIs) and surgical resection. The aim of our study was to investigate the efficacy of this therapeutic approach. Studies reporting outcomes for patients underwent liver resection from metastatic gastrointestinal stromal tumor (GIST) were overviewed. Eleven studies were included, which enrolled 240 patients with liver metastasis from GISTs. A median overall survival (OS) interval of 41.8 months was calculated while a median disease free interval of 17.9 [17-43] months following resection was also measured. Recurrences were recorded in 63 patients. Prognostic factors identified by the studies included surgical resection, R0 resection, age <55 years, clinical response to TKIs, pre- and postoperative administration of TKIs. The included studies highlight the importance of complete resection and the timing of resection, as well underline the importance of pre- and post-operative administration of TKIs.
胃肠道间质瘤（GIST）肝转移（LM）的推荐治疗方案包括围手术期给予酪氨酸激酶抑制剂（TKIs）和手术切除。我们研究的目的是调查这种治疗方法的疗效。对报告转移性胃肠道间质瘤（GIST）肝切除患者结局的研究进行了综述。纳入了11项研究，共纳入240例GIST肝转移患者。计算出中位总生存期（OS）为41.8个月，同时还测量了切除术后中位无病生存期为17.9 [17 - 43]个月。63例患者出现复发。这些研究确定的预后因素包括手术切除、R0切除、年龄<55岁、对TKIs的临床反应、术前和术后给予TKIs。纳入的研究强调了完全切除和切除时机的重要性，同时也强调了术前和术后给予TKIs的重要性。
